Every 0.1mL on your syringe contains exactly 0.1mg
About the SELECT trial SELECT was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of Wegovy (semaglutide 2.4 mg) versus placebo as an adjunct to standard of care for the prevention of MACE in people with overweight or obesity and established CVD with no prior history of diabetes
Blood Pressure Tirzepatide 10 mg was associated with a numerically greater decrease in SBP and tirzepatide 5 and 15 mg numerically smaller decreases in SBP (mmHg) compared with liraglutide
When we try to look at the effects on glucose and insulin and doing what we call dose response experiments, where we increase the dose to see how much you can actually obtain with this, then we also found, as we increased the doses, people would start to get sick
The lower absolute weight loss compared to STEP 1 reflects the metabolic challenges specific to type 2 diabetes, but the improvement remained highly significant